FEATURESPACE
16.8.2022 16:02:11 CEST | Business Wire | Press release
Featurespace and Vital4 have signed a global partnership to provide the financial services industry with AI driven Watchlist, PEPs, Sanctions and Adverse Media screening through Featurespace’s award winning ARIC Risk Hub. With this partnership, ARIC Risk Hub for AML is a one stop, end-to-end financial crime prevention solution for the customer.
Through a single API, ARIC Risk Hub for AML will leverage the watchlist data collected and curated by Vital4 to enhance the performance of Featurespace’s self learning models, ultimately improving accuracy and reducing false positives in flagged entities and transactions. Vital4’s automated AML/ KYC data tools analyze more than 6,000 global watchlists to help identify subjects involved in sanctions, terrorism, or corruption.
“Given the complementary technologies of Featurespace and Vital4, the industry now has access to behavioral analytics coupled with sentiment analysis to truly identify the financial criminals in real time.” Said Dave Excell, Featurespace Founder.
Vital4’s AI driven system examines 13 important criteria to provide the highest levels of name-matching, removing the ambiguity of legacy systems that rely on fuzzy name matching that can miss critical data points.
“As financial crime becomes increasingly complex to combat, crossing borders and moving in real-time, AML professionals need a complete risk hub to effectively monitor and report suspicious transactions and remain compliant.” Said Amy Barbieri, Co-Founder and President of Vital4. “The risk of non-compliance has huge reputational impact, making the business case clear for technologies that improve the accuracy for anti-financial crime efforts”.
Featurespace and Vital4 are two Atlanta based AI driven technology companies led by industry leading women. The two companies are unified around a shared commitment to enable banks and financial instutions with the best technology to fight financial crime and make the world a safer place to transact.
Primary industry benefits:
AI Driven Watchlist Screening :
- Machine learning to manage increasing volume and variety of transactions and entities to screen and monitor
- Monitoring over 6,300 Watchlists and Global Sanctions in 200+ countries and regions
- Propriety entity and name matching to provide more accurate search results and reduce false positives
- Proprietary 13-point name matching algorithm – better than traditional fuzzy name matching logic
- Natural Language Processing and Sentiment Analysis to truly identify Adverse Media articles AI-powered tagging of individuals or businesses in articles
- Watchlists updated real-time
- Risk-based call-out depending on business rule logic, analytics output
Customer Screening
- Screening at onboarding, change of details and ongoing trigger-based or scheduled monitoring
- Risk-based screening policies determine depth of search
- Watchlist flags available for analysts and immediate use within rules
Real-time Transaction Screening
- Real-time enabled sanctions screening of specified transaction types (i.e. cross-border, wires, ACH)
- Screening of counterparties
- Instant responses and action tags
- Reviewed in context of wider account activity a single, intuitive UI
Featurespace continues to partner with best in class technologies to provide holistic FRAML solutions for smart thinking financial institutions. Featurespace's partnership with Vital4 provides customers with a consolidated view and ability to manage financial crime risks across AML, fraud and sanctions within a single next generation risk management platform. Featurespace’s partnership with Callsign provides Enhanced Authentication and Device ID and security is provided by Accertify, and Ciphertrace provides crypto intelligence for transactional monitoring.
About Featurespace
Featurespace is the world leader in enterprise grade technology that prevents fraud and fights financial crime. With a mission to make the world a safer place to transact, Featurespace helps banks and financial institutions protect consumers, and reduce risk and operating costs by providing industry-leading machine learning, financial crime prevention solutions. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks and is the first to profile both genuine and fraudulent behavior to identify and catch criminal activity in real time. Both are patent pending technologies that are central to Featurespace’s award winning ARIC™ Risk Hub. Over 70 direct customers and 100,000 merchants and financial institutions have put their trust in Featurespace’s technology including HSBC, NatWest, TSYS, Worldpay, Marqeta, Contis, Danske Bank, Akbank, Edenred and Permanent TSB. Founded in 2008, and headquartered in Cambridge, UK Featurespace has a team of over 400, operating globally from seven locations.
About Vital4
Vital4 is an award-winning global technology company that provides critical data to organizations for regulatory compliance and to help mitigate third-party risk. Striving to make the world a safer place, Vital4 helps identify illicit actors in the fight against financial crime, terrorism, fraud, and corruption. Vital4 was founded with four fundamental concepts in mind: compliance, accuracy, global insight, and value. The powerful search platform, Vital4Search, was built with a “tech first” approach anchored by AI and Machine learning and is the world’s fastest and most accurate proprietary data search technology on the market today. Vital4Search solves enterprise compliance problems by eliminating slow update cycles, shallow source pools and reducing the human error risk of manual legacy processes. Vital4 provides data solutions to thousands of users in banking, gaming, identity, gig economy, GRC, legal, insurance and 4 of the top 5 largest background screening companies in the world put their trust in Vital4.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
